The World Obesity Atlas 2023 projects that by 2035, over 4 billion people globally could be classified as overweight or obese, a sharp increase from 2.6 billion in 2020
In patients with T2D and multiple risk factors for ASCVD but without established disease, meta-analyses have not detected a MACE benefit for GLP-1RA or SGLT2 inhibitors
She even suggested I consider a switch to a brand new med that was a combination of a GLP-1 receptor agonist + GIP receptor agonist
In addition to FDAs general warning that compounded products are risky for patients, there are numerous recent examples of specific threats to public health from pharmacy compounding
If someone is unsure, the simplest approach is to take B12 with water and keep the schedule consistent
This enhanced efficacy is due to semaglutides ability to achieve greater receptor activation, amplifying appetite suppression and promoting a caloric deficit